PUVA or NBUVB for mycosis fungoides?

The Dermatologist. 2019.

Phototherapy is a very popular treatment option for mycosis fungoides, and with good reason. High levels of efficacy and low rates of adverse events make light therapy a viable treatment option for many patients. This article compares narrowband UVB to psoralen UVA phototherapy in treating mycosis fungoides. Findings state that either option could be used in treating early-stages of the disease.

Full Article

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Full Article Yiu Z, Ashcroft D, Evans I, McElhone K, Lunt M, Smith C, Walton S, Murphy R, Reynolds N, Ormerod A, Griffiths C, Warren

Moderate exercise and bright light treatment in overweight and obese individuals

Full Article Dunai A, Novak M, Chung S, Kayumov L, Keszei A, Levitan R, Shapiro C Obesity. 2007;15(7):1749-1757. “This randomized, controlled study is the first

Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study

Full Article Malanos D Stern R J Am Acad Dermatol. 2007;57(2):231-7. doi:10.1016/j.jaad.2007.04.027 A common fear associated with the use of psoralen plus ultraviolet A (PUVA)

PUVA or NBUVB for mycosis fungoides?

Other Articles

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Moderate exercise and bright light treatment in overweight and obese individuals

Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study

CALL 1-800-DAAVLIN OR FILL OUT THE FORM BELOW

CALL 1-800-DAAVLIN OR
FILL OUT THE FORM BELOW